Nuvo Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, revenue was CAD 36.59 million compared to CAD 34.21 million a year ago. Net income was CAD 20.32 million compared to net loss of CAD 8.84 million a year ago. Basic earnings per share from continuing operations was CAD 1.78 compared to basic loss per share from continuing operations of CAD 0.78 a year ago. Diluted earnings per share from continuing operations was CAD 0.42 compared to diluted loss per share from continuing operations of CAD 0.78 a year ago.